Dr. Patrick C. Roche Net Worth

The estimated Net Worth of Patrick C. Roche is at least $56.2 Tisíc dollars as of 10 March 2016. Dr Roche owns over 5,929 units of HTG Molecular Diagnostics Inc stock worth over $9,193 and over the last 9 years he sold HTGM stock worth over $47,004.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Dr Roche HTGM stock SEC Form 4 insiders trading

Dr has made over 5 trades of the HTG Molecular Diagnostics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 5,929 units of HTGM stock worth $14,111 on 10 March 2016.

The largest trade he's ever made was buying 6,500 units of HTG Molecular Diagnostics Inc stock on 18 August 2015 worth over $37,440. On average, Dr trades about 1,491 units every 12 days since 2015. As of 10 March 2016 he still owns at least 19,152 units of HTG Molecular Diagnostics Inc stock.

You can see the complete history of Dr Roche stock trades at the bottom of the page.

Dr. Patrick C. Roche biography

Dr. Patrick C. Roche is the Sr. VP of R&D at HTG Molecular Diagnostics Inc.

How old is Dr Roche?

Dr Roche is 68, he's been the Sr. VP of R&D of HTG Molecular Diagnostics Inc since . There are 2 older and 13 younger executives at HTG Molecular Diagnostics Inc. The oldest executive at HTG Molecular Diagnostics Inc is Harry George, 71, who is the Independent Director.

What's Dr Roche's mailing address?

Patrick's mailing address filed with the SEC is C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON, AZ, 85706.

Insiders trading at HTG Molecular Diagnostics Inc

Over the last 9 years, insiders at HTG Molecular Diagnostics Inc have traded over $5,630,772 worth of HTG Molecular Diagnostics Inc stock and bought 1,019,150 units worth $14,128,765 . The most active insiders traders include Plc Gsk, Holdings A/S Novo a Laurence W Lytton. On average, HTG Molecular Diagnostics Inc executives and independent directors trade stock every 64 days with the average trade being worth of $28,039. The most recent stock trade was executed by Stephen Barat on 8 June 2023, trading 888 units of HTGM stock currently worth $710.

What does HTG Molecular Diagnostics Inc do?

about htg molecular diagnostics: headquartered in tucson, arizona, htg's mission is to empower precision medicine at the local level. in 2013 the company commercialized its htg edge instrument platform and a portfolio of rna assays that leverage htg's proprietary nuclease protection chemistry. htg's product offerings have since expanded to include its htg edgeseq product line, which automates sample and targeted library preparation for next-generation sequencing. additional information is available at www.htgmolecular.com.

Complete history of Dr Roche stock trades at HTG Molecular Diagnostics Inc

HTG Molecular Diagnostics Inc executives and stock owners

HTG Molecular Diagnostics Inc executives and other stock owners filed with the SEC include:

• John Lubniewski,
  President, Chief Executive Officer, Director
• John L. Lubniewski,
  Pres, CEO & Director
• Shaun D. McMeans,
  Sr. VP, CFO, Sec. & Treasurer
• Shaun McMeans,
  Chief Financial Officer, Senior Vice President, Treasurer, Secretary
• Byron T. Lawson,
  Sr. VP & Chief Commercial Officer
• Timothy Johnson,
  Executive Chairman of the Board
• Byron Lawson,
  Senior Vice President and Chief Commercial Financial Officer
• Lee McCracken,
  Independent Director
• James LaFrance,
  Independent Director
• Donnie Hardison,
  Independent Director
• Michelle Griffin,
  Independent Director
• Harry George,
  Independent Director
• Ann Hanham,
  Lead Independent Director
• Laura Beggrow,
  Pres of Diagnostics
• Dr. Stephen A. Barat Ph.D.,
  Sr. VP of Therapeutics
• Dr. Marian Navratil Ph.D.,
  Sr. VP of R&D
• Dr. Patrick C. Roche,
  Sr. VP of R&D
• Dr. Debra A. Gordon,
  Sr. VP & Chief Legal Counsel
• Laura Lee Godlewski,
  Sr. VP of Fin. & Admin.
• Dr. Maureen T. Cronin Ph.D.,
  Sr. VP & Chief Scientific Officer
• Christopher P Kiritsy,
  Director
• Stephen Barat,
  Senior VP of Therapeutics
• Debra A Gordon,
  V.P. and Chief Legal Counsel
• Lewis Shuster,
  Director
• Plc Gsk,
  10% owner
• Don M Hardison,
  Director
• Holdings A/S Novo,
  10% owner
• Nv Qiagen,
  10% owner
• Patrick C. Roche,
  SVP Research & Development
• Spaght Ventures Ii Lpfsv Ii...,
  
• Donald W Grimm,
  Director
• Capital Ventures Llc Senour...,
  
• Tim B Johnson,
  Executive Chairman
• Laurence W Lytton,
  10% owner
• Thomas W. Dubensky,
  Director
• Laura Lee Godlewski,
  SVP Finance & Administration